StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) stock

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$4.76−0.41 (-7.93%)

Close on Nov 19, 2026Market cap $257.83MP/E –Yield –

Eikon Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$65.21M–
Q1 FY2026Mar 31, 2026-$90.06M–
Q2 FY2025Jun 30, 2025-$54.45M–
Q1 FY2025Mar 31, 2025-$76.88M–

More Eikon Therapeutics figures

See a number that looks wrong?